374 related articles for article (PubMed ID: 28276858)
1. The safety of second-line treatment options for non-small cell lung cancer.
Rossi A; Maione P; Santabarbara G; Sacco PC; Casaluce F; Sgambato A; Barzelloni ML; Palazzolo G; Gridelli C
Expert Opin Drug Saf; 2017 Apr; 16(4):471-479. PubMed ID: 28276858
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE
Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis.
Créquit P; Chaimani A; Yavchitz A; Attiche N; Cadranel J; Trinquart L; Ravaud P
BMC Med; 2017 Oct; 15(1):193. PubMed ID: 29082855
[TBL] [Abstract][Full Text] [Related]
4. Safety profiles of first-line therapies for metastatic non-squamous non-small-cell lung cancer.
Losanno T; Gridelli C
Expert Opin Drug Saf; 2016 Jun; 15(6):837-51. PubMed ID: 27007279
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
6. Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology.
Dhillon S
Target Oncol; 2015 Jun; 10(2):303-10. PubMed ID: 25894578
[TBL] [Abstract][Full Text] [Related]
7. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH; Soo RA
Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
[TBL] [Abstract][Full Text] [Related]
8. Novel drugs against non-small-cell lung cancer.
Pirker R
Curr Opin Oncol; 2014 Mar; 26(2):145-51. PubMed ID: 24406751
[TBL] [Abstract][Full Text] [Related]
9. Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy.
Gridelli C; Ascierto PA; Grossi F; Baldini E; Favaretto A; Garassino MC; Morabito A; Migliorino MR; Rossi A; de Marinis F
Curr Clin Pharmacol; 2018; 13(2):76-84. PubMed ID: 29992894
[TBL] [Abstract][Full Text] [Related]
10. Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer.
Losanno T; Rossi A; Maione P; Napolitano A; Gridelli C
Expert Opin Biol Ther; 2016 Jun; 16(6):747-58. PubMed ID: 26950292
[TBL] [Abstract][Full Text] [Related]
11. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
[TBL] [Abstract][Full Text] [Related]
13. Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials.
Connock M; Armoiry X; Tsertsvadze A; Melendez-Torres GJ; Royle P; Andronis L; Clarke A
BMC Cancer; 2019 Apr; 19(1):392. PubMed ID: 31023244
[TBL] [Abstract][Full Text] [Related]
14. EGFR TKI combination with immunotherapy in non-small cell lung cancer.
Ahn MJ; Sun JM; Lee SH; Ahn JS; Park K
Expert Opin Drug Saf; 2017 Apr; 16(4):465-469. PubMed ID: 28271729
[TBL] [Abstract][Full Text] [Related]
15. [A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker].
Wislez M; Malka D; Bennouna J; Mortier L; Bensadoun RJ; Sicard J; Dielenseger P; Rey JB; Moro-Sibilot D; Scotté F
Bull Cancer; 2014 Jun; 101(6):647-52. PubMed ID: 24977454
[TBL] [Abstract][Full Text] [Related]
16. Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma.
Burotto M; Ali SA; O'Sullivan Coyne G
Expert Opin Drug Saf; 2015 Jan; 14(1):97-110. PubMed ID: 25345687
[TBL] [Abstract][Full Text] [Related]
17. Nintedanib in non-small cell lung cancer: from preclinical to approval.
Caglevic C; Grassi M; Raez L; Listi A; Giallombardo M; Bustamante E; Gil-Bazo I; Rolfo C
Ther Adv Respir Dis; 2015 Aug; 9(4):164-72. PubMed ID: 25855060
[TBL] [Abstract][Full Text] [Related]
18. Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.
Nishiyama A; Katakami N; Yoshioka H; Iwasaku M; Korogi Y; Hata A; Takeshita J; Otsuka K; Nishino K; Uchida J; Okuyama T; Namba Y; Mori M; Fujita S; Morita S
Lung Cancer; 2015 Sep; 89(3):301-5. PubMed ID: 26141215
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
Shukuya T; Ko R; Mori K; Kato M; Yagishita S; Kanemaru R; Honma Y; Shibayama R; Koyama R; Shimada N; Takahashi K
Cancer Chemother Pharmacol; 2015 Oct; 76(4):771-6. PubMed ID: 26259641
[TBL] [Abstract][Full Text] [Related]
20. Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).
Ardizzoni A; Tiseo M
J Chemother; 2004 Nov; 16 Suppl 4():104-7. PubMed ID: 15688623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
